

Association between hepatic fat and subclinical vascular disease burden in the general population

Xinting Cai ,^{1,2} Susanne Rospleszcz,^{1,3,4} Birger Mensel,⁵ Ulf Schminke,⁶ Jens-Peter Kühn,⁷ Ali Alexander Aghdassi,⁸ Corinna Storz,⁹ Roberto Lorbeer,¹⁰ Christopher L Schlett,¹¹ Wolfgang Rathmann,^{12,13} Michael Roden,^{13,14,15} Simon Hohenester,¹⁶ Robin Bülow,¹⁷ Fabian Bamberg,¹¹ Annette Peters,^{1,4,18,19} Barbara Thorand,^{1,19} Henry Völzke,^{20,21} Jana Nano^{1,19}

To cite: Cai X, Rospleszcz S, Mensel B, *et al.* Association between hepatic fat and subclinical vascular disease burden in the general population. *BMJ Open Gastro* 2021;**8**:e000709. doi:10.1136/bmjgast-2021-000709

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjgast-2021-000709>).

Received 14 May 2021
Accepted 27 July 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Jana Nano;
jana.nano@helmholtz-muenchen.de

ABSTRACT

Objective It is still controversial if increased hepatic fat independently contributes to cardiovascular risk. We aimed to assess the association between hepatic fat quantified by MRI and various subclinical vascular disease parameters.

Design We included two cross-sectional investigations embedded in two independent population-based studies (Study of Health in Pomerania (SHIP): n=1341; Cooperative Health Research in the Region of Augsburg (KORA): n=386). The participants underwent a whole-body MRI examination. Hepatic fat content was quantified by proton-density fat fraction (PDFF). Aortic diameters in both studies and carotid plaque-related parameters in KORA were measured with MRI. In SHIP, carotid intima-media thickness (cIMT) and plaque were assessed by ultrasound. We used (ordered) logistic or linear regression to assess associations between hepatic fat and subclinical vascular disease.

Results The prevalence of fatty liver disease (FLD) (PDFF >5.6%) was 35% in SHIP and 43% in KORA. In SHIP, hepatic fat was positively associated with ascending (β , 95% CI 0.06 (0.04 to 0.08)), descending (0.05 (0.04 to 0.07)) and infrarenal (0.02 (0.01 to 0.03)) aortic diameters, as well as with higher odds of plaque presence (OR, 95% CI 1.22 (1.05 to 1.42)) and greater cIMT (β , 95% CI 0.01 (0.004 to 0.02)) in the age-adjusted and sex-adjusted model. However, further adjustment for additional cardiometabolic risk factors, particularly body mass index, attenuated these associations. In KORA, no significant associations were found.

Conclusions The relation between hepatic fat and subclinical vascular disease was not independent of overall adiposity. Given the close relation of FLD with cardiometabolic risk factors, people with FLD should still be prioritised for cardiovascular disease screening.

INTRODUCTION

Fatty liver disease (FLD), defined as an ectopic fat accumulation ($\geq 5\%$) in the hepatocytes, constitutes the leading cause of chronic liver disease worldwide.¹ With a growing prevalence of 2%–44% in the general population,

Summary box

What is already known about this subject?

► Fatty liver disease and subclinical vascular disease share several common cardiometabolic risk factors, such as type 2 diabetes and obesity. There is not yet population-based study to investigate the association between hepatic fat content and the expansion of aortic diameters. Epidemiological studies on the relation between fatty liver disease and atherosclerosis yielded controversial results.

What are the new findings?

► With data from the general population, we found that hepatic fat content measured with MRI was neither independently associated with greater aortic diameters nor the risk of carotid plaque, after adjusting for cardiometabolic risk factors, especially obesity.

How might it impact on clinical practice in the foreseeable future?

► Given that fatty liver disease is closely related to concurrent obesity, type 2 diabetes and other cardiometabolic disorders, people with fatty liver disease should still be recommended to monitor their cardiovascular risk factors and prioritised for cardiovascular disease screening.

clinical manifestations of FLD ranging from simple steatosis, steatohepatitis, fibrosis and eventually cirrhosis and hepatocellular carcinoma pose a substantial burden on health-care systems.² In particular, cardiovascular disease (CVD), one of the extrahepatic repercussions of FLD, remains to be the largest contributor of mortality among people with FLD.³

Prior to the clinical manifestation of CVD, subclinical vascular disease, representing pathological changes of various blood vessels, can provide important aetiological insights into early detection of CVD development.⁴ We have previously shown with our data

that hepatic fat was positively associated with subclinical vascular parameters such as left ventricular remodelling index.⁵ Moreover, data from other population-based studies have also indicated a positive association between FLD and subclinical calcified plaque in different vessels.^{6,7}

One understudied outcome of interest in the realm of subclinical vascular changes is aortic aneurysm, which represents a disproportionate dilation of aortic diameter (thoracic aorta diameter ≥ 5 cm or abdominal aorta diameter ≥ 3 cm) that could result in life-threatening events such as aortic rupture or dissection.⁸ Several risk factors for the development of aortic aneurysm including age, increased body mass index (BMI) and hyperlipidaemia are mutually shared with FLD.⁹ However, whether hepatic fat is associated with expanding aortic diameters, measured along multiple locations of the aorta, has not been previously investigated in a population-based setting.

Furthermore, the evidence is still inconsistent regarding whether hepatic fat represents an independent modifiable risk factor for subclinical atherosclerosis, such as carotid plaque. A meta-analysis reported that compared with people without FLD those who with FLD were almost 80% more likely to have carotid plaque detected by ultrasound.¹⁰ However, different criteria used for defining carotid plaque made their conclusions unconvincing. Ultrasound is less precise than CT or MRI in quantifying plaque calcification, which is particularly prone to progress to CVD events.¹¹ Interestingly, two well-powered population-based studies could not show a link between FLD and carotid calcification measured by CT.^{12,13} On the other hand, most previous studies used either ultrasound or CT to define FLD, which are less sensitive than MRI when fat content is low.¹⁴

Therefore, we aimed to determine the association of hepatic fat quantified by dedicated whole-body MRI protocols with aortic diameters and carotid atherosclerosis measured by MRI or ultrasound in two well-characterised independent German studies.

METHODS

Study population

The Study of Health in Pomerania

The baseline examination of the Study of Health in Pomerania (SHIP)—TREND-0 (SHIP-TREND-0 abbreviated as SHIP) was conducted between 2008 and 2012 and included participants from West Pomerania, north-eastern part of Germany. The study design has previously been described in detail.¹⁵ Out of 8826 adults (20–79 years) randomly drawn from local population registries, a sample of 4420 eligible participants completed the baseline examination including personal interviews, laboratory measurements, ultrasonography and simple medical examinations.¹⁵ After excluding participants with MRI contraindication or who refused to participate (n=2492), 1926 participants underwent a whole-body MRI examination. Exclusion criteria for MRI examination were described elsewhere.¹⁶ Further exclusion criteria for the present analysis included not fasting at the time of medical examination, missing values for hepatic fat measurements or any covariate (n=585) leading to a total of 1341 participants for the final analyses (figure 1).

The Cooperative Health Research in the Region of Augsburg Study

Cooperative Health Research in the Region of Augsburg (KORA) FF4 study, conducted between 2013 and 2014, was the second follow-up study of the KORA S4 survey (conducted between 1999 and 2001). We used the data from a subpopulation of the KORA FF4 study, which was originally selected for a nested case-control study to detect subclinical CVD in individuals with pre-diabetes and diabetes compared with those with normal glucose tolerance. Of all 4261 participants of the S4 survey, 2279 participants also participated in the FF4 study. The inclusion and exclusion criteria of the KORA-FF4-MRI (abbreviated as KORA) protocol were described elsewhere.¹⁷ A total of 400 participants underwent the whole-body MRI examination. They were free of overt CVD events, such as stroke, myocardial infarction and peripheral artery diseases. Finally, due to missing values in MRI-measured




Figure 1 Flowchart of the study design. CAD, coronary artery disease; CVD, cardiovascular; KORA, Cooperative Health Research in the Region of Augsburg; PAD, peripheral artery disease; SHIP, Study of Health in Pomerania.



hepatic fat content (n=14), the final population included in the analyses comprised 386 participants (figure 1).

Both studies comply with the Declaration of Helsinki. The SHIP study was approved by the Ethics Committee of University of Greifswald (BB 39/08). The KORA study was approved by the institutional review board of the Medical Faculty of Ludwig-Maximilian University Munich (06068). All participants provided written informed consent.

Assessment of hepatic fat content and subclinical vascular parameters

Hepatic fat content was estimated by MRI proton-density fat fraction (PDFF, %) at the level of portal vein in both SHIP and KORA (see online supplemental materials 1 for the MRI device and sequence used). FLD was defined according to the Clinical Practice Guidelines for the management of non-alcoholic FLD¹⁸: No FLD (PDFF \leq 5.6%) versus with FLD (PDFF $>$ 5.6%).

The diameters (cm) of the ascending, descending and infrarenal aorta were measured in axial plane both in SHIP and KORA with MRI. As for carotid injury, in SHIP, the carotid intima-media thickness (cIMT) (mm) was measured with ultrasound and averaged over the left carotid artery (LCA) and the right carotid artery (RCA). Carotid plaque presence was adjudicated if any of the following three criteria was met: any focal thickening of the intima-media complex protruding into the vessel lumen, a focal increase in echogenicity with a homogeneously hyperechoic echotexture within an otherwise hypoechoic intima-media complex, a uniformly increased cIMT ($>$ 1.3 mm) without focal thickening. In KORA, presence and morphological composition of carotid plaque were determined in the MRI protocol. Mean wall thickness (mm), lumen area (mm²) and wall area (mm²) were separately calculated for the LCA and the RCA. Normalised wall index (NWI), as calculated with wall area/(lumen area + wall area), describes the percentage of the wall surface in proportion to the total blood vessel surface. According to the presence of calcification and haemorrhage as well as wall thickness and wall eccentricity, plaque was differentiated and classified to type I, type III, type IV/V and type VI/VII with the criteria of the American Heart Association.¹⁹ Participants with type III, type IV/V or type VI/VII plaque were considered as having carotid plaque.

Traditional cardiovascular risk factors and other covariates

Other covariates were assessed in both studies, including traditional cardiovascular risk factors—such as BMI (kg/m²), waist circumference (cm), smoking status (smoker, ex-smoker, never smoker), physically active (yes, no), alcohol consumption (no intake, moderate intake, excessive intake: \geq 20 g/day for women or \geq 30 g/day for men), hypertension (yes, no), systolic blood pressure (SBP) (mm Hg), diastolic blood pressure (mm Hg), total cholesterol (mmol/L), high-density lipoprotein cholesterol (HDL-C) (mmol/L), low-density lipoprotein

cholesterol (LDL-C) (mmol/L), triglycerides (mmol/L) and liver enzymes (aspartate aminotransferase (AST) (μ kat/L), alanine aminotransferase (ALT) (μ kat/L), gamma-glutamyl transferase (GGT) (μ kat/L)). Visceral adipose tissue (VAT) in litre was also measured in the whole-body MRI protocols. Participants were divided into three groups according to their glucose tolerance status: normoglycaemic (fasting glucose $<$ 6.1 mmol/L and 2 hour glucose $<$ 7.8 mmol/L), pre-diabetes (2 hour glucose between 7.8 mmol/L and 11.0 mmol/L and normal fasting glucose or fasting glucose between 6.1 mmol/L and 6.9 mmol/L and normal 2 hour glucose) and diabetes (fasting glucose $>$ 6.9 mmol/L and/or 2 hour glucose $>$ 11.0 mmol/L) following each study protocols.^{15 17} Medication use within the last 7 days prior to the interview, such as use of antihypertensive²⁰ and lipid-lowering medication, was ascertained in both studies. In SHIP, history of CVD included events of myocardial infarction, stroke and angina pectoris. A detailed description of the MRI device measurements, the sequence used for hepatic fat content and subclinical vascular disease parameters and the definitions of other covariates are provided in online supplemental materials 1.^{15–27}

Statistical analyses

We calculated the descriptive variables separately for SHIP and KORA as well as for the groups: participants with FLD (PDFF $>$ 5.6%) versus participants without FLD (PDFF \leq 5.6%) within each study. For continuous variables, we displayed mean (SD) if they were normally distributed, and median (IQR) if the distribution was not normal. We show categorical variables with counts (percentages, %). We used two-sample t-test for comparison of continuous variables and χ^2 test for comparison of categorical variables. We log-transformed the variables that did not follow a normal distribution including triglycerides, ALT, AST, GGT in both studies, wall thickness of RCA and LCA, lumen area of RCA and LCA and wall area of RCA and LCA in KORA.

The coefficient estimates represent the change in subclinical disease parameters corresponding to one SD increase in log-transformed hepatic fat content. In both studies, we conducted linear regressions to examine the associations between hepatic fat content and continuous outcomes and logistic regression for categorical outcomes. The following three models were constructed for both SHIP and KORA. In model 1, we adjusted for age and sex. In model 2, we additionally included BMI. In model 3, we further adjusted for smoking, physical activity, alcohol intake, SBP, HDL-C, LDL-C, triglycerides, glucose tolerance status, history of CVD (in SHIP), use of antihypertensive medication and use of lipid-lowering medication. Considering the potential collinearity among the cardiometabolic covariates in model 3, we also calculated variance inflation factor for each covariate,²⁸ which refuted the existence of strong collinearity among the covariates. The same models were conducted with FLD (yes vs no), as an important clinical endpoint of excessive

hepatic fat. The interactions between hepatic fat content (or FLD) and diabetes as well as obesity ($\text{BMI} \geq 30 \text{ kg/m}^2$) were examined by entering a multiplicative term (PDFF \times diabetes or PDFF \times obesity) in the models. The interaction between hepatic fat and history of CVD (PDFF \times CVD) was only assessed in SHIP.

In addition, sensitivity analyses were conducted in both studies excluding participants with excessive alcohol intake, defined as a daily alcohol intake $\geq 30 \text{ g}$ for men and $\geq 20 \text{ g}$ for women.¹⁸ Kühn *et al* have suggested another cut-off of PDFF ($>5.1\%$) for FLD based on histopathologic calibrations.²¹ We also conducted sensitivity analyses with FLD (yes vs no) defined by this cut-off in both studies. In order to examine the influence of visceral adiposity, we substituted BMI with VAT or waist circumference as a covariate in the models. Further sensitivity analyses excluding participants with a history of CVD were conducted in SHIP.

The significance level was set to a nominal p value <0.05 . Data analysis was performed with R-Studio V.4.0.2.

RESULTS

Table 1 summarises the baseline characteristics for the participants from the SHIP and KORA studies. Participants with a valid PDFF measurement consisted of 612 (45.6%) men and 729 (54.4%) women in SHIP and 223 (57.8%) men and 163 (42.2%) women in KORA. Mean age was lower in SHIP (50.4 ± 13.7 years) than in KORA (56.2 ± 9.1 years). Moreover, participants in SHIP had lower waist circumference, were more physically active, suffered less from pre-diabetes and diabetes, but had higher prevalence of hypertension, compared with participants from KORA. Median PDFF and prevalence of FLD were lower in SHIP (469, 35.0%) than in KORA (166, 43.0%). We present demographic, anthropometric, lifestyle, cardiometabolic profiles stratified by FLD in both studies in online supplemental table 1.

Aortic diameters were greater among SHIP participants (ascending aorta: $3.32 \pm 0.46 \text{ cm}$; descending aorta: $2.46 \pm 0.35 \text{ cm}$; infrarenal aorta: $1.85 \pm 0.23 \text{ cm}$) than among KORA participants (ascending aorta: $2.96 \pm 0.41 \text{ cm}$; descending aorta: $2.09 \pm 0.31 \text{ cm}$; infrarenal aorta: $1.50 \pm 0.21 \text{ cm}$). The presence of carotid plaque was more frequent in SHIP ($n=467$, 34.9%) than in KORA ($n=54$, 20.6%). Morphological features of the plaque are listed in table 2. They are not comparable between the two studies due to different methods. Subclinical vascular parameters according to FLD in both studies are presented in online supplemental table 2.

Associations between hepatic fat content and aortic diameters

In SHIP, one SD increase in hepatic fat content was significantly associated with greater ascending (β , 95% CI 0.06 (0.04 to 0.08)), descending (0.05 (0.04 to 0.07)) and infrarenal (0.02 (0.01 to 0.03)) aortic diameters in model 1. Further adjustment for BMI (model 2) substantially

Table 1 Characteristics of study participants in SHIP and KORA

	SHIP	KORA
	Total (N=1341)	Total (N=386)
Age (years)	50.4 (13.7)	56.2 (9.1)
Women	729 (54.4%)	163 (42.2%)
BMI (kg/m^2)	27.4 (4.4)	28.1 (4.9)
Waist circumference (cm)	88.9 (12.9)	98.5 (14.3)
Physically active	960 (71.6%)	230 (59.6%)
Smoking		
Smoker	289 (21.6%)	77 (19.9%)
Ex-smoker	486 (36.2%)	169 (43.8%)
Never smoker	566 (42.2%)	140 (36.3%)
Alcohol consumption		
No intake	164 (12.2%)	92 (23.8%)
Moderate intake	1091 (81.4%)	191 (49.5%)
Excessive intake	86 (6.4%)	103 (26.7%)
Systolic blood pressure (mm Hg)	125.1 (16.8)	120.6 (16.8)
Diastolic blood pressure (mm Hg)	76.6 (9.7)	75.3 (10.0)
Hypertension	539 (40.2%)	132 (34.2%)
Total cholesterol (mmol/L)	5.5 (1.1)	5.6 (0.9)
HDL-C (mmol/L)	1.5 (0.4)	1.6 (0.5)
LDL-C (mmol/L)	3.4 (0.9)	3.6 (0.9)
Triglycerides (mmol/L)	1.2 (0.9, 1.7)	1.2 (0.9, 1.8)
ALT ($\mu\text{kat/L}$)	0.4 (0.3, 0.5)	0.5 (0.3, 0.6)
AST ($\mu\text{kat/L}$)	0.3 (0.2, 0.4)	0.4 (0.3, 0.5)
GGT ($\mu\text{kat/L}$)	0.5 (0.4, 0.7)	0.5 (0.3, 0.7)
Glucose tolerance status		
Normoglycaemic	932 (69.5%)	239 (61.9%)
Pre-diabetes	281 (21.0%)	95 (24.6%)
Diabetes	128 (9.5%)	52 (13.5%)
PDFF (%)	3.85 (2.32, 7.74)	4.62 (2.63, 11.89)
FLD	469 (35.0%)	166 (43.0%)
Antihypertensive medication use	369 (27.5%)	98 (25.4%)
Lipid-lowering medication use	109 (8.1%)	41 (10.6%)
History of CVD	93 (6.9%)	NA

Values are expressed as the mean (SD) for normally distributed continuous variables or median (IQR) for non-normally distributed continuous variables, or n (%) for categorical variables.

Hepatic fat content was quantified on the level of portal vein by MRI PDFF. FLD (PDFF $>5.6\%$) was defined according to the European Association for the Study of the Liver (EASL)-European Association for the Study of Diabetes (EASD)-European Association for the Study of Obesity (EASO) Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CVD, cardiovascular disease; FLD, fatty liver disease; GGT, gamma-glutamyl transferase; HDL-C, high-density lipoprotein cholesterol; KORA, Cooperative Health Research in the Region of Augsburg; LDL-C, low-density lipoprotein cholesterol; PDFF, proton density fat fraction; SHIP, Study of Health in Pomerania.

attenuated the estimates. Adding other cardiometabolic risk factors in model 3 changed the results only marginally.



Table 2 Subclinical vascular disease parameters among participants in SHIP and KORA

	SHIP	KORA
	Total (N=1341)	Total (N=386)
Ascending aorta diameter (cm)	3.32 (0.46)	2.96 (0.41)
Descending aorta diameter (cm)	2.46 (0.35)	2.09 (0.31)
Infrarenal aorta diameter (cm)	1.85 (0.23)	1.50 (0.21)
Plaque presence	467 (34.9%)	54 (20.6%)
Type of plaque	NA	
AHA type I		208 (79.4%)
AHA type III		38 (14.5%)
AHA type V		10 (3.8%)
AHA type VI or VII		6 (2.3%)
Carotid intima-media thickness (mm)	0.60 (0.14)	NA
Wall thickness, LCA (mm)	NA	0.73 (0.69, 0.79)
Wall thickness, RCA (mm)	NA	0.73 (0.69, 0.81)
Lumen area, LCA (mm ²)	NA	17.54 (14.02, 21.61)
Lumen area, RCA (mm ²)	NA	16.40 (13.14, 20.68)
Wall area, LCA (mm ²)	NA	12.39 (10.72, 14.03)
Wall area, RCA (mm ²)	NA	12.18 (10.36, 14.06)
NWI, LCA	NA	0.44 (0.05)
NWI, RCA	NA	0.45 (0.05)

Values are expressed as the mean (SD) for continuous variables, or n (%) for categorical variables.

Hepatic fat content was quantified on the level of portal vein by MRI PDFF. Plaque was detected using ultrasound in SHIP and MRI in KORA. Number of missing values for each outcome variable is shown in online supplemental table 2.

AHA, American Heart Association; KORA, Cooperative Health Research in the Region of Augsburg; LCA, left carotid artery; NA, not applicable; NWI, normalised wall index, calculated as wall area/(lumen area + wall area); PDFF, proton density fat fraction; RCA, right carotid artery; SHIP, Study of Health in Pomerania.

In KORA, hepatic fat content and aortic diameters were not significantly associated in all three models (table 3) (model 3: ascending aorta: β , 95% CI -0.04 (-0.09 to 0.02); descending aorta: -0.03 (-0.07 to 0.01) and infrarenal aorta: -0.01 (-0.04 to 0.01)).

Associations between hepatic fat content and carotid plaque and related parameters

In SHIP, one SD increase of hepatic fat content was associated with higher odds of plaque presence (OR, 95% CI 1.22 (1.05 to 1.42)) and greater cIMT (β , 95% CI 0.01 (0.004 to 0.02)) in model 1. Further adjustment for BMI in model 2 attenuated these associations (plaque presence: OR, 95% CI 1.13 (0.95 to 1.33) and cIMT: β , 95% CI 0.002 (-0.01 to 0.01)). Further adjustment for other cardiometabolic risk factors (model 3) changed the results only marginally.

In KORA, we did not observe any significant associations between hepatic fat content and plaque-related outcomes including plaque presence (model 3: OR, 95% CI 0.80 (0.49 to 1.29)) and plaque type (0.73 (0.45 to 1.19)) (table 3). Regression analyses with the morphological

features of plaque revealed non-significant estimates in all models (table 3).

Sensitivity analysis

The interaction terms between hepatic fat content and diabetes/obesity/CVD in SHIP were not significant. In KORA, we found significant interactions between hepatic fat content and diabetes for plaque presence ($p_{\text{PDFF} \times \text{diabetes}} = 0.031$) and plaque type ($p_{\text{PDFF} \times \text{diabetes}} = 0.020$). Due to the enrichment of participants with altered glucose metabolism (pre-diabetes and diabetes) in KORA, we did subgroup analyses stratified by glycaemic status (normoglycaemia vs pre-diabetes or diabetes). Among participants with altered glucose metabolism, carotid plaque presence (OR, 95% CI 0.44 (0.21 to 0.91)) and plaque type (0.39 (0.19 to 0.79)) were inversely associated with hepatic fat content after full adjustment (online supplemental table 3).

Considering the role of alcohol intake in the pathogenesis of FLD, we also conducted sensitivity analyses excluding participants with excessive alcohol intake.¹⁸ The latter did not change the estimates except for NWI of the RCA in KORA, which was significantly inversely associated with hepatic fat only in model 3 (β , 95% CI -0.01 (-0.02 to -0.0004)). Very likely this represents a spurious findings due to the large number of tests (online supplemental table 4). Therefore, most likely we can generalise our results to the context of non-alcoholic FLD.

Regression analyses with FLD (yes vs no) as exposure, defined by either cut-off of PDFF (5.6% or 5.1%), showed similar non-significant coefficient estimates in both studies (online supplemental table 5). Replacing BMI with either VAT or waist circumference as a covariate did not influence the results in both studies (online supplemental table 5). In SHIP, sensitivity analyses excluding participants with a history of CVD hardly affected the results (online supplemental table 6).

DISCUSSION

In this investigation comprising two cross-sectional investigations embedded in two independent population-based studies, we found no association between increasing hepatic fat content measured by MRI and parameters of subclinical vascular disease, including (ascending, descending, infrarenal) aortic diameters and carotid plaque presence and its morphological features. The link between hepatic fat content and subclinical vascular parameters was mainly driven by general adiposity and other cardiometabolic risk factors, such as hyperlipidemia and hypertension, which very often coexist with FLD. This indicates that the role of hepatic fat on subclinical vascular burden might be rather a reflection of worsened cardiometabolic profile.

Hepatic fat content and aortic diameters

The present investigation is the first to report the association between increasing hepatic fat and aortic diameters in a population-based setting. A clinical study from


Table 3 Associations of hepatic fat content with subclinical vascular disease parameters in SHIP and KORA studies

	N	Model 1	P value	Model 2	P value	Model 3*	P value
SHIP							
<i>Aortic diameters</i>		β, 95% CI		β, 95% CI		β, 95% CI	
Ascending aorta (cm)	1209	0.06 (0.04 to 0.08)	<0.001	0.01 (−0.02 to 0.03)	0.469	0.001 (−0.02 to 0.03)	0.913
Descending aorta (cm)	1209	0.05 (0.04 to 0.07)	<0.001	0.01 (−0.01 to 0.02)	0.228	0.01 (−0.01 to 0.02)	0.533
Infrarenal aorta (cm)	1209	0.02 (0.01 to 0.03)	<0.001	−0.01 (−0.02 to 0.01)	0.282	−0.001 (−0.01 to 0.01)	0.837
<i>Carotid plaque</i>		OR, 95% CI		OR, 95% CI		OR, 95% CI	
Plaque presence	1339	1.22 (1.05 to 1.42)	0.008	1.13 (0.95 to 1.33)	0.178	1.03 (0.85 to 1.25)	0.753
Carotid intima-media-thickness (mm)		β, 95% CI		β, 95% CI		β, 95% CI	
	1339	0.01 (0.004 to 0.02)	0.002	0.002 (−0.01 to 0.01)	0.538	−0.003 (−0.01 to 0.004)	0.401
KORA							
<i>Aortic diameters</i>		β, 95% CI		β, 95% CI		β, 95% CI	
Ascending aorta (cm)	367	0.03 (−0.01 to 0.07)	0.166	−0.03 (−0.08 to 0.02)	0.202	−0.04 (−0.09 to 0.02)	0.168
Descending aorta (cm)	367	0.01 (−0.02 to 0.04)	0.385	−0.03 (−0.06 to 0.002)	0.070	−0.03 (−0.07 to 0.01)	0.110
Infrarenal aorta (cm)	367	0.02 (−0.004 to 0.03)	0.115	−0.01 (−0.03 to 0.02)	0.536	−0.01 (−0.04 to 0.01)	0.349
<i>Carotid plaque</i>		OR, 95% CI		OR, 95% CI		OR, 95% CI	
Plaque presence	262	0.93 (0.66 to 1.32)	0.676	0.84 (0.56 to 1.25)	0.390	0.80 (0.49 to 1.29)	0.354
Plaque type	262	0.93 (0.66 to 1.31)	0.692	0.80 (0.53 to 1.20)	0.274	0.73 (0.45 to 1.19)	0.206
Wall thickness, LCA (mm)		β, 95% CI		β, 95% CI		β, 95% CI	
	251	0.01 (−0.01 to 0.03)	0.474	−0.01 (−0.03 to 0.01)	0.186	−0.02 (−0.04 to 0.01)	0.179
Wall thickness, RCA (mm)		β, 95% CI		β, 95% CI		β, 95% CI	
	257	0.01 (−0.01 to 0.02)	0.534	−0.01 (−0.03 to 0.01)	0.193	−0.01 (−0.03 to 0.01)	0.287
Lumen area, LCA (mm ²)		β, 95% CI		β, 95% CI		β, 95% CI	
	255	0.02 (−0.03 to 0.06)	0.481	−0.01 (−0.06 to 0.05)	0.841	0.001 (−0.06 to 0.06)	0.968
Lumen area, RCA (mm ²)		β, 95% CI		β, 95% CI		β, 95% CI	
	262	0.03 (−0.02 to 0.08)	0.266	−0.003 (−0.06 to 0.05)	0.915	0.04 (−0.03 to 0.10)	0.271
Wall area, LCA (mm ²)		β, 95% CI		β, 95% CI		β, 95% CI	
	251	0.01 (−0.02 to 0.05)	0.414	−0.02 (−0.06 to 0.02)	0.288	−0.02 (−0.06 to 0.03)	0.448
Wall area, RCA (mm ²)		β, 95% CI		β, 95% CI		β, 95% CI	
	257	0.02 (−0.01 to 0.06)	0.173	−0.01 (−0.05 to 0.03)	0.537	−0.01 (−0.04 to 0.05)	0.827
NWI, LCA		β, 95% CI		β, 95% CI		β, 95% CI	
	251	0.001 (−0.01 to 0.01)	0.675	−0.002 (−0.01 to 0.01)	0.642	−0.003 (−0.01 to 0.01)	0.453
NWI, RCA		β, 95% CI		β, 95% CI		β, 95% CI	
	257	−0.002 (−0.01 to 0.004)	0.454	−0.003 (−0.01 to 0.004)	0.370	−0.01 (−0.02 to −0.00003)	0.061

Model 1: adjusted for age, sex.

Model 2: model 1+BMI

Model 3: model 2+smoking status, physical activity, alcohol intake, systolic blood pressure, HDL-C, LDL-C, triglycerides, glucose tolerance status, use of antihypertensive medication, use of lipid-lowering medication.

Results with p value<0.05 are shown in bold. The coefficient estimates represent the change in subclinical disease parameters with a SD increment of log-transformed hepatic fat content.

*Model 3 in SHIP was additionally adjusted for history of cardiovascular diseases.

β, β-estimates from linear regression; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; KORA, Cooperative Health Research in the Region of Augsburg; LCA, left carotid artery; LDL-C, low-density lipoprotein cholesterol; NWI, normalised wall index, calculated as wall area/(lumen area+wall area); RCA, right carotid artery; SHIP, Study of Health in Pomerania.

Mahamid *et al*, including data from 495 hospitalised patients with abdominal aortic aneurysm (AAA) diagnosed with either ultrasound or CT and 500 matched controls, reported a positive relation between FLD and AAA occurrence adjusted for age, smoking, BMI and metabolic syndrome.⁹ However, these results should be interpreted with caution given the highly selective sample of hospitalised patients, who were diagnosed with a clinically relevant and more advanced stage of infrarenal aorta dilation (≥ 3 cm),²⁹ which could have biased the results.

FLD and AAA share common pathophysiological risk factors such as adiposity, insulin resistance and inflammation. In our study, the adjustment for BMI substantially attenuated the associations of hepatic fat with aortic diameters. Accordingly, previous animal studies have shown that leptin secreted by adipocytes could promote proinflammatory cytokines, for example, interleukin-18,

binding to their receptors on aortic smooth muscle cells. Consequently, adipocytes could enhance aortic inflammation and exacerbate AAA development.³⁰ Because of the close relation between hepatic fat and central obesity, we also substituted BMI with better measurements of visceral adiposity such as waist circumference and VAT, the latter measured with MRI. The results did not change. This indicates that higher general or central adiposity, which often coexists with FLD, confounds the association between hepatic fat content and increasing aortic diameters. Therefore, an independent effect of hepatic fat in the aetiology of AAA could not be shown.

Hepatic fat content, carotid plaque and related parameters

Previous studies have yielded controversial results regarding the association between FLD and subclinical carotid atherosclerosis. The largest meta-analysis to date with studies assessing FLD and carotid plaque defined by

ultrasound revealed a positive association between these two parameters.¹⁰ Although cIMT provides insight into continuous change of vessel walls over time, the clinical cut-off point of cIMT that distinguishes people with increased cardiovascular risk varied among the studies. Moreover, the meta-analysis included different methods for determining FLD, either by ultrasound or biopsy. Although biopsy remains the gold standard for diagnosing FLD, it is prone to sampling error.³¹ Ultrasound has limited performance in detecting FLD at a milder stage.³¹ Due to these heterogeneities in measuring methods, the conclusion of this meta-analysis is less convincing and remains a controversial.

On the other side, results from two population-based studies suggested that FLD is not an independent risk factor for subclinical carotid plaque.^{12 13} In an investigation using data from the Rotterdam Study, Wolff *et al* found that higher hepatic fat measured by CT was related to increasing volumes of coronary artery, yet not to carotid artery calcification.¹² Similar results were found in another study using CT scans from Koo *et al*, where they showed that FLD was positively associated with calcification in thoracic aorta and coeliac trunk, but not carotid artery. The distinct atherogenic effects of FLD on different vascular beds may reflect different underlying mechanisms. The location of subclinical alterations with regards to FLD merits emphasis in future studies.

In line with previous literature in population-based setting,^{12 13} we found no evidence of an independent role of hepatic fat on carotid plaque development. An observation from Di Costanzo *et al* found that cIMT only increased among people with FLD sharing other metabolic abnormalities, but not in people with FLD without metabolic abnormalities, compared with controls without FLD.³² It might be plausible that FLD does not add to the burden of carotid atherosclerosis, unless it coexists with metabolic abnormalities. In addition, other studies in settings enriched with patients with type 2 diabetes found no independent association between FLD and subclinical carotid plaque, after adjustment for insulin resistance.^{33–35} It has been indicated by previous studies that insulin resistance could be a major factor increasing cardiovascular risks of people with FLD.³⁶ In the Tübingen Diabetes Family Study with participants at higher risk of diabetes, researchers have shown that insulin resistance increased with higher hepatic fat content measured by MRI,³⁷ mainly caused by imbalance of adipocytokines.³⁸ Moreover, insulin resistance could promote inflammation and endothelial dysfunction, two major factors of an atherogenic environment.³⁹ These evidences pointed out that ectopic fat accumulation in liver might be regarded as a hepatic manifestation of metabolic dysfunction.

While certainly not wanting to overlook the clinical relevance of FLD, focus should be laid on assessing and treating metabolic dysfunction of FLD people as an attempt to reduce CVD risk. In light of the new definition for metabolic dysfunction-associated FLD, the level of cardiovascular risks among metabolically unhealthy

people with FLD is equally high, regardless of obesity.^{40 41} Although we did not find an independent role of hepatic fat on subclinical vascular disease that extends beyond overall adiposity and other cardiometabolic risk factors, we still think it is important for continue screening patients with FLD for CVD.

Strengths and limitations

This is the first study to investigate the association between hepatic fat content/FLD and subclinical vascular changes in both aorta and carotid artery by whole-body MRI examination. With data from two cross-sectional investigations embedded in population-based cohorts, we were able to show the consistency of the associations. Both studies collected data on a variety of cardiometabolic and lifestyle risk factors that were considered in the model adjustment and allowed for examining potential differences in subgroups in the sensitivity analyses. Moreover, MRI demonstrates the best overall performance in determining FLD,⁴² and it is also highly sensitive and specific for carotid plaque imaging.⁴³

Some limitations need to be addressed. The MRI protocols used in SHIP and KORA were not able to distinguish more advanced stage of FLD involving fibrosis (using, eg, elastography) from simple steatosis, which could potentially modify the association between hepatic fat and subclinical vascular diseases. Despite the two different measuring modalities for carotid plaque (ultrasound in SHIP and MRT in KORA), the consistent null result indicated that the lack of association is unlikely to be due to methodological discrepancy. Additionally, due to the cross-sectional design of our study, we could only capture the relationship between hepatic fat content and subclinical vascular parameters at one point of time. This design does not allow for interpretation on the directionality of associations. Given that fat accumulation in liver is modifiable,³⁸ whether the elevation/amelioration of hepatic fat could accelerate/reverse the development of subclinical vascular diseases over time warrants further investigation.

CONCLUSION

We found that the associations between hepatic fat measured with MRI and subclinical vascular disease such as aortic diameters and subclinical atherosclerosis parameters were not independent of overall adiposity and a worsened cardiometabolic risk profile. Given the close relation of hepatic fat to other cardiometabolic risk factors, such as obesity, dyslipidaemia, hypertension and diabetes, we cannot afford to overlook the role of FLD on CVD development. Therefore, people with FLD should still be strongly advised to modify their CVD risks, such as overall adiposity, which can be targeted with lifestyle interventions. Well-powered prospective cohort studies with state-of-the-art imaging modalities are needed to better understand the contribution of hepatic fat in subclinical vascular disease development.

Author affiliations

- ¹Institute of Epidemiology, Helmholtz Center Munich German Research Center for Environmental Health, Neuherberg, Germany
- ²Institute for Medical Information Processing, Biometry, and Epidemiology—IBE, Pettenkofer School of Public Health, Ludwig-Maximilians-Universität München, Munich, Germany
- ³Department of Epidemiology, Institute for Medical Information Processing, Biometry and Epidemiology—IBE, Ludwig-Maximilians-Universität München, Munich, Germany
- ⁴German Center for Cardiovascular Disease Research (DZHK), partner site Munich Heart Alliance, Munich, Germany
- ⁵Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Jena, Germany
- ⁶Department of Neurology, University Medicine Greifswald, Greifswald, Germany
- ⁷Institute and Policlinic for Diagnostic and Interventional Radiology, University Hospital Carl-Gustav-Carus, Dresden University of Technology, Dresden, Germany
- ⁸Department of Internal Medicine A, University Medicine Greifswald, Greifswald, Germany
- ⁹Department of Neuroradiology, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany
- ¹⁰Department of Radiology, University Hospital, LMU Munich, Munich, Bayern, Germany
- ¹¹Department of Diagnostic and Interventional Radiology, Medical Center-University of Freiburg, Freiburg, Germany
- ¹²Institute for Biometrics and Epidemiology, German Diabetes Center Leibniz Institute for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- ¹³Partner site Düsseldorf, German Center for Diabetes Research, Neuherberg, Germany
- ¹⁴Department of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- ¹⁵Institute for Clinical Diabetology, German Diabetes Center, German Diabetes Center Leibniz Institute for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- ¹⁶Department of Medicine II, University Hospital, LMU Munich, Munich, Germany
- ¹⁷Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany
- ¹⁸Institute for Medical Information Processing, Biometry, and Epidemiology—IBE, Ludwig Maximilians University Munich, Munich, Germany
- ¹⁹Partner site Munich-Neuherberg, German Center for Diabetes Research, Neuherberg, Germany
- ²⁰Institute for Community Medicine, SHIP/Clinical-Epidemiological Research, University Medicine Greifswald, Greifswald, Germany
- ²¹Partner site Greifswald, German Center for Cardiovascular Disease Research, Greifswald, Germany

Contributors All persons listed as coauthors have contributed to preparing the manuscript: XC has designed the analyses, interpreted the data and drafted the manuscript; SR has contributed to the conception and design of the data analyses; JN has contributed to conception, design and interpretation of the data and approval of the manuscript; BM, US, J-PK, AAA, CS, RL, CLS, WR, MR, SH, RB, FB, AP, BT and HV have contributed substantially to the interpretation of the data and have critically revised the manuscript for important intellectual content. BT and HV are responsible for the overall content as guarantors.

Funding The Study of Health in Pomerania (SHIP) is part of the Community Medicine Research Network of the University Medicine Greifswald, which is supported by the German Federal Ministry of Education and Research (BMBF, grant numbers: 01ZZ96030 and 01ZZ0701). MRI scans in SHIP-TREND-0 have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The KORA research platform and the MONICA/KORA Augsburg studies are financed by the Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. The KORA-MRI sub-study received funding by the German Research Foundation (DFG, grant number: BA 4233/4-1), and German Centre for Cardiovascular Disease Research (DZHK, Berlin, Germany, grant numbers: 81X2600209 and 81X2600214). This study was funded by a grant from the German Center for Diabetes Research (DZD-NEXT) to Jana Nano

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The datasets generated and/or analysed during the current study are not publicly available due to data protection reasons. The data are available in an anonymised form on reasonable request to the corresponding author.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Xinting Cai <http://orcid.org/0000-0003-1837-3289>

REFERENCES

- 1 Younossi Z, Anstee QM, Marietti M, *et al*. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2018;15:11–20.
- 2 Blachier M, Leleu H, Peck-Radosavljevic M, *et al*. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol* 2013;58:593–608.
- 3 Adams LA, Anstee QM, Tilg H, *et al*. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut* 2017;66:1138–53.
- 4 Ingelsson E, Sullivan LM, Fox CS, *et al*. Burden and prognostic importance of subclinical cardiovascular disease in overweight and obese individuals. *Circulation* 2007;116:375–84.
- 5 Schlett CL, Lorbeer R, Arndt C, *et al*. Association between abdominal adiposity and subclinical measures of left-ventricular remodeling in diabetics, prediabetics and normal controls without history of cardiovascular disease as measured by magnetic resonance imaging: results from the KORA-FF4 study. *Cardiovasc Diabetol* 2018;17:88.
- 6 Mellinger JL, Pencina KM, Massaro JM, *et al*. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the framingham heart study. *J Hepatol* 2015;63:470–6.
- 7 Kapuria D, Takyar VK, Etzion O, *et al*. Association of hepatic steatosis with subclinical atherosclerosis: systematic review and meta-analysis. *Hepatol Commun* 2018;2:877–87.
- 8 Kälsch H, Lehmann N, Möhlenkamp S, *et al*. Body-surface adjusted aortic reference diameters for improved identification of patients with thoracic aortic aneurysms: results from the population-based heinz Nixdorf recall study. *Int J Cardiol* 2013;163:72–8.
- 9 Mahamid M, Khoury T, Mahamid B, *et al*. The interplay between abdominal aortic aneurysm, metabolic syndrome and fatty liver disease: a retrospective case-control study. *Diabetes Metab Syndr Obes* 2019;12:12.
- 10 Madan SA, John F, Prysopoulos N, *et al*. Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis. *Eur J Gastroenterol Hepatol* 2015;27:1237–48.
- 11 Syed MB, Fletcher AJ, Forsythe RO, *et al*. Emerging techniques in atherosclerosis imaging. *Br J Radiol* 2019;92:20180309.
- 12 Wolff L, Bos D, Murad SD, *et al*. Liver fat is related to cardiovascular risk factors and subclinical vascular disease: the rotterdam study. *Eur Heart J Cardiovasc Imaging* 2016;17:1361–7.
- 13 Koo BK, Allison MA, Criqui MH, *et al*. The association between liver fat and systemic calcified atherosclerosis. *J Vasc Surg* 2020;71:e4:204–11.
- 14 Li Q, Dhyani M, Grajo JR, *et al*. Current status of imaging in nonalcoholic fatty liver disease. *World J Hepatol* 2018;10:530–42.
- 15 Völzke H, Alte D, Schmidt CO, *et al*. Cohort profile: the study of health in pomerania. *Int J Epidemiol* 2011;40:294–307.

- 16 Kühn J-P, Meffert P, Heske C, *et al.* Prevalence of fatty liver disease and hepatic iron overload in a northeastern German population by using quantitative MR imaging. *Radiology* 2017;284:706–16.
- 17 Bamberg F, Hetterich H, Rospleszcz S, *et al.* Subclinical disease burden as assessed by whole-body MRI in subjects with prediabetes, subjects with diabetes, and normal control subjects from the general population: the KORA-MRI study. *Diabetes* 2017;66:158–69.
- 18 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;64:1388–402.
- 19 Cai J-M, Hatsukami TS, Ferguson MS, *et al.* Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. *Circulation* 2002;106:1368–73.
- 20 Scholze J. Empfehlungen zur hochdruckbehandlung in der praxis. *Notfall & Hausarztmedizin* 2005;31:152–9.
- 21 Kühn J-P, Hernando D, Muñoz del Río A, *et al.* Effect of multiplex spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. *Radiology* 2012;265:133–42.
- 22 Zhong X, Nickel MD, Kannengiesser SAR, *et al.* Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. *Magn Reson Med* 2014;72:1353–65.
- 23 Lorbeer R, Bayerl C, Auweter S, *et al.* Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. *J Hypertens* 2017;35:737–44.
- 24 Mensel B, Heßelbarth L, Wenzel M, *et al.* Thoracic and abdominal aortic diameters in a general population: MRI-based reference values and association with age and cardiovascular risk factors. *Eur Radiol* 2016;26:969–78.
- 25 Saam T, Ferguson MS, Yarnykh VL, *et al.* Quantitative evaluation of carotid plaque composition by in vivo MRI. *Arterioscler Thromb Vasc Biol* 2005;25:234–9.
- 26 Holle R, Happich M, Löwel H, *et al.* KORA—a research platform for population based health research. *Gesundheitswesen* 2005;67 Suppl 1:19–25.
- 27 World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation, 2006. Available: https://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/
- 28 Crane TA, Surlis JG. Model-dependent variance inflation factor cutoff values. *Qual Eng* 2002;14:391–403.
- 29 Mathur A, Mohan V, Ameta D, *et al.* Aortic aneurysm. *J Transl Int Med* 2016;4:35–41.
- 30 Liu C-L, Ren J, Wang Y, *et al.* Adipocytes promote interleukin-18 binding to its receptors during abdominal aortic aneurysm formation in mice. *Eur Heart J* 2020;41:2456–68.
- 31 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *World J Gastroenterol* 2014;20:475.
- 32 Di Costanzo A, D'Erasmo L, Polimeni L, *et al.* Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically- versus genetically-driven excess fat hepatic storage. *Atherosclerosis* 2017;257:232–9.
- 33 McKimmie RL, Daniel KR, Carr JJ, *et al.* Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study. *Am J Gastroenterol* 2008;103:3029–35.
- 34 Petit JM, Guiu B, Terriat B, *et al.* Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. *J Clin Endocrinol Metab* 2009;94:4103–6.
- 35 Targher G, Bertolini L, Padovani R, *et al.* Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. *J Endocrinol Invest* 2006;29:55–60.
- 36 Stefan N, Häring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. *Lancet Diabetes Endocrinol* 2019;7:313–24.
- 37 Stefan N, Kantartzis K, Machann J, *et al.* Identification and characterization of metabolically benign obesity in humans. *Arch Intern Med* 2008;168:1609–16.
- 38 Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. *Nat Clin Pract Endocrinol Metab* 2006;2:335–48.
- 39 Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. *Cell Metab* 2011;14:575–85.
- 40 Eslam M, Newsome PN, Sarin SK, *et al.* A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. *J Hepatol* 2020;73:202–9.
- 41 Ampuero J, Aller R, Gallego-Durán R, *et al.* The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. *Aliment Pharmacol Ther* 2018;48:1260–70.
- 42 Qayyum A, Chen DM, Breiman RS, *et al.* Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? *Clin Imaging* 2009;33:110–5.
- 43 Brinjikji W, Huston J, Rabinstein AA, *et al.* Contemporary carotid imaging: from degree of stenosis to plaque vulnerability. *J Neurosurg* 2016;124:27–42.

SUPPLEMENTAL MATERIALS

Methods (continues)

Assessment of hepatic fat content by magnetic resonance imaging (MRI)

In SHIP, a 1.5-T MRI (Magnetom Avanto; Siemens Healthcare AG, Germany) was performed by using a 12-channel phased-array coil. A three-echo confounder-corrected chemical shift-encoded MRI protocol acquired the imaging of the upper abdominal organs ¹. The following parameters were used: repetition time (msec)/echo time 1 (msec)/echo time 2 (msec)/echo time 3 (msec), 11.0/2.4/4.8/9.6; flip angle, 10°; one signal average; bandwidth, 1065 Hz/pixel; 224 × 126 × 32 matrix; field of view, 410 × 308; section thickness, 6.0 mm; and monopolar readout.

Following image acquisition, intrahepatic lipid content was estimated by proton-density fat fraction (PDFF, %) by using an offline reconstruction algorithm written in Matlab (Mathworks, Natick, Mass) ². PDFF maps were generated on a pixel-by-pixel basis with correction for T2* decay, T1 bias, noise bias, eddy current, multipeak spectral complexity of fat. Operator-defined selection of the entire liver excluding the central portal vein and inferior vena cava was performed in one section by using the region-of-interest tool in Osirix version 4.6; Pixmeo, Bernex, Switzerland). ³

In KORA, MRI examinations were performed at a 3-T Magnetom Skyra (Siemens Healthcare AG, Germany) using an 18-channel body coil in combination with the table-mounted spine matrix coil ⁴. The participants were scanned in the supine position.

Intrahepatic lipid content at the level of portal vein was estimated by PDFF measurement with a multiecho Dixon sequence with six echo times. It was based on a volume interpolated body

examination sequence with the following parameters: repetition time 8.90 ms, six echo times ranging from 1.23 to 7.38 ms, flip angle 4°, matrix 256 × 256. Slice thickness was 4 mm. For the estimation of hepatic PDFF, confounding effects of T2⁺ decay and the spectral complexity of fat were taken into account⁵. T1 effect could be ignored due to the small flip angle used. Acquisition time was around 15 s. Data were analysed by a dedicated software package (Osirix, Ver. 4.1 64-bit; Pixmeo SARL, Bernex, GE, Switzerland). At the height of the portal vein, a region of interest was drawn on one slice including the whole liver parenchyma avoiding large vessels and surrounding extrahepatic tissue to measure hepatic fat content at the level of portal vein⁶.

Assessment of aortic diameters by MRI

In SHIP, the outer diameters (cm) of the ascending and descending aorta were measured at the level of the pulmonary trunk. The infrarenal aorta diameter (cm) was measured 1 cm below the right renal artery origin. Aorta images were viewed and processed, and the diameters were measured on axial slices in coronal orientation from outer wall to outer wall with the software OsiriX (version 3.6.1; Pixmeo Sarl, Bernex, Switzerland).⁷

In KORA, the measurement of maximal aortic diameters was conducted by a gradient echo sequence, and the imaging data were further assessed by the 3D-function of a dedicated software (Syngo.via, Siemens). The maximal anterior–posterior diameter (cm) of the ascending and descending aorta at the level of right pulmonary artery was measured. Infrarenal aorta was located in a 3D coronal and sagittal view of the abdomen. The maximal anterior-posterior diameter (cm) of the infrarenal aorta was measured in the axial direction of the cross-section.

Assessment of subclinical carotid plaque

In SHIP, certified medical examiners assessed the extracranial carotid arteries for plaques and carotid intima-media thickness (cIMT) with B-mode ultrasound (vivid-I, GE Medical Systems, Waukesha, Wisconsin, WI, USA) with an operating frequency of 13 MHz. Any plaque presence in the common carotid arteries (CCA), the bifurcations and the internal and external carotid arteries was defined.

Scans from the distal straight portion of the CCA on both sides were recorded. The mean far-wall IMT was measured semi-automatically on screen using an edge tracking software, which calculates a mean value by averaging approximately 250 measurements at an arterial segment of 1 cm in length. Mean cIMT (mm) was calculated as the following: (right mean cIMT + left mean cIMT)/2. If only one side had available information, the value of the available side was taken as the mean cIMT.

In KORA, presence and morphological composition of carotid plaque was determined on black-blood, T1-weighted, fat-suppressed sequences on both sides of the distal CCA, at the carotid bulb, and in the proximal internal carotid artery^{8,9}. Boundary of the vessel lumen and the vessel wall were analyzed for all 14 consecutive slices using commercially available semiautomatic software (CASCADE; University of Washington, Seattle, the United States).

Traditional cardiovascular risk factors and other covariates

In SHIP, trained interviewers conducted computer-assisted personal interviews for the assessment of demographic, lifestyle and medical history. Blood samples were obtained and stored according to standardized procedures. The laboratory took part in the official German

external quality proficiency testing programs¹. In KORA, information on the covariates was obtained from standardized interviews and questionnaires described elsewhere in detail¹⁰. For both studies, body mass index (BMI) was calculated as weight (kg) divided by height squared (m²), whereas obesity was defined as BMI more than 30 kg/m². Waist circumference (cm) was measured at the level midway between the lower rib margin and the iliac crest while the participants breathed out gently. According to smoking habits, participants were categorized into never smoker, ex-smoker and smoker. In SHIP, participants were classified as physically active if they regularly participated in sports for ≥ 1 h/week in summer or winter, otherwise they were classified as physically inactive. In KORA, the duration of leisure time sport activity in winter and summer was assessed separately as follows: >2 h/week (scored 1), 1-2 h/week (scored 2), <1 h/week (scored 3), none (scored 4). Possible scores for summer and winter were summed up to generate a total score for physical activity. Participants were classified as 'physically inactive' if they had a total score ≥ 5 , and 'physically active' otherwise. Average alcohol intake per day were calculated from self-reported consumption of beer, wine and distilled spirits within the past month in SHIP, and over the previous weekend and workday in KORA. Excessive alcohol intake was defined in case of alcohol intake ≥ 20 g/day for women or ≥ 30 g/day for men¹¹. Alcohol intake was categorized into no intake, moderate intake and excessive intake. Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg, or currently receiving antihypertensive treatment if participants were aware of having hypertension. Blood lipids levels included total cholesterol (mmol/L), high-density lipoprotein cholesterol (HDL-C) (mmol/L), low-density lipoprotein cholesterol (LDL-C) (mmol/L) and triglycerides (mmol/L). As markers of liver disease severity, levels of aspartate aminotransferase (AST) (μ kat/l), alanine aminotransferase (ALT) (μ kat/l) and gamma-glutamyl transferase (GGT) (μ kat/l) were measured in the blood serum with the Dimension Vista System (Siemens

Healthcare AG, Germany). Imbedded in the whole body MRI protocols, visceral adipose tissue (VAT) in liter was measured from the diaphragm to the bladder in SHIP, and from the femoral head to the diaphragm in KORA.

Glucose tolerance status included normoglycaemia, prediabetes and diabetes. In SHIP, self-reported diabetes or antidiabetic medication intake together with the oral glucose tolerance test (OGTT) measurements (fasting glucose > 6.9 mmol/L and/or 2h glucose > 11.0 mmol/L) was considered when defining diabetes. In KORA, diabetes was defined by clinically validated diagnosis or OGTT measurement (fasting glucose > 6.9 mmol/L and/or 2h glucose > 11.0 mmol/L) for participants without validated diagnosis⁴. In both studies, prediabetes was defined by OGTT as impaired glucose tolerance (2h glucose between 7.8 and 11.0 mmol/L and normal fasting glucose) or impaired fasting glucose (fasting glucose between 6.1 and 6.9 mmol/L and normal 2h glucose)¹². Normoglycaemia was defined if fasting glucose < 6.1 mmol/L and 2h glucose < 7.8 mmol/L by OGTT.

Intake of medication in the last seven days prior to the interview was ascertained.

Antihypertensive medication comprised antihypertensive effective compounds classified by the most recent guidelines¹³. Lipid-lowering medication included use of statins and fibrates in SHIP. In KORA, aside from statins and fibrates use, other lipid-modifying agents, such as omega-3 fatty acids, were also included among lipid-lowering medications.

References

1. Völzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania. *Int J Epidemiol* 2011;40(2):294-307.
2. Kühn J-P, Hernando D, Muñoz del Rio A, et al. Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. *Radiology* 2012;265(1):133-42.
3. Kühn J-P, Meffert P, Heske C, et al. Prevalence of fatty liver disease and hepatic iron overload in a northeastern German population by using quantitative MR imaging. *Radiology* 2017;284(3):706-16.
4. Bamberg F, Hetterich H, Rospleszcz S, et al. Subclinical disease burden as assessed by whole-body MRI in subjects with prediabetes, subjects with diabetes, and normal control subjects from the general population: the KORA-MRI study. *Diabetes* 2017;66(1):158-69.
5. Zhong X, Nickel MD, Kannengiesser SA, et al. Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. *Magn Reson Med* 2014;72(5):1353-65.
6. Lorbeer R, Bayerl C, Auweter S, et al. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. *J Hypertens* 2017;35(4):737-44.
7. Mensel B, Heßelbarth L, Wenzel M, et al. Thoracic and abdominal aortic diameters in a general population: MRI-based reference values and association with age and cardiovascular risk factors. *Eur Radiol* 2016;26(4):969-78.
8. Cai J, Hatsukami TS, Ferguson MS, et al. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. *Circulation* 2002;106(11):1368-73.
9. Saam T, Ferguson M, Yarnykh V, et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. *Arterioscler Thromb Vasc Biol* 2005;25(1):234-39.
10. Holle R, Happich M, Löwel H, et al. KORA-a research platform for population based health research. *Das Gesundheitswesen* 2005;67(S 01):19-25.

11. EASL, EASD, EASO. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;9(2):65-90.
12. World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Available via https://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/
13. Scholze J. Empfehlungen zur Hochdruckbehandlung in der Praxis. *Notfall & Hausarztmedizin* 2005;31(04):152-59. doi: 10.1055/s-2005-869560

Supplemental tables

Supplemental table I. Study characteristics of study participants with and without fatty liver disease (FLD) in SHIP and KORA.

	SHIP			KORA		
	No FLD (N=872) (65%)	FLD (N=469) (35%)	<i>p</i> value	No FLD (N=220) (57%)	FLD (N=166) (43%)	<i>p</i> value
Age(years)	47.7 (13.9)	55.5 (11.7)	< 0.001	54.5 (9.2)	58.3 (8.6)	< 0.001
Women	521 (59.7%)	208 (44.3%)	< 0.001	117 (53.2%)	46 (27.7%)	< 0.001
BMI (kg/m²)	25.8 (3.7)	30.5 (3.9)	< 0.001	26.0 (4.0)	30.8 (4.7)	< 0.001
Waist Circumference(cm)	83.6 (11.0)	98.5 (10.4)	< 0.001	91.5 (11.7)	107.9 (11.9)	< 0.001
Physically active	639 (73.3%)	321 (68.4%)	0.061	147 (66.8%)	83 (50.0%)	< 0.001
Smoking			0.007			< 0.001
smoker	206 (23.6%)	83 (17.7%)		56 (25.5%)	21 (12.7%)	
ex-smoker	293 (33.6%)	193 (41.2%)		78 (35.5%)	91 (54.8%)	
never smoker	373 (42.8%)	193 (41.2%)		86 (39.1%)	54 (32.5%)	
Alcohol consumption			0.005			0.201
no intake	106 (12.2%)	58 (12.4%)		55 (25.0%)	37 (22.3%)	
moderate intake	724 (83.0%)	367 (78.3%)		114 (51.8%)	77 (46.4%)	
excessive intake	42 (4.8%)	44 (9.4%)		51 (23.2%)	52 (31.3%)	
Systolic blood pressure (mmHg)	121.3 (16.0)	132.3 (15.8)	< 0.001	115.7 (15.1)	127.2 (16.8)	< 0.001
Diastolic blood pressure (mmHg)	74.5 (9.1)	80.5 (9.7)	< 0.001	73.0 (9.0)	78.3 (10.4)	< 0.001
Hypertension	253 (29.0%)	286 (61.0%)	< 0.001	47 (21.4%)	85 (51.2%)	< 0.001
Total cholesterol (mmol/l)	5.4 (1.1)	5.7 (1.0)	< 0.001	5.6 (0.9)	5.7 (1.0)	0.430
HDL-C (mmol/l)	1.6 (0.4)	1.3 (0.3)	< 0.001	1.7 (0.5)	1.5 (0.4)	< 0.001
LDL-C (mmol/l)	3.3 (0.9)	3.6 (0.9)	< 0.001	3.6 (0.8)	3.7 (0.9)	0.129
Triglyceride s(mmol/l)	1.0 (0.8, 1.4)	1.6 (1.2, 2.2)	< 0.001	1.0 (0.8, 1.4)	1.6 (1.2, 2.2)	< 0.001
ALT (μkat/l)	0.3 (0.2, 0.4)	0.5 (0.4, 0.7)	< 0.001	0.4 (0.3, 0.5)	0.6 (0.5, 0.8)	< 0.001
AST (μkat/l)	0.3 (0.2, 0.3)	0.3 (0.3, 0.4)	< 0.001	0.3 (0.3, 0.4)	0.4 (0.4, 0.6)	< 0.001
GGT (μkat/l)	0.4 (0.4, 0.6)	0.6 (0.5, 0.9)	< 0.001	0.4 (0.2, 0.5)	0.7 (0.4, 1.1)	< 0.001
Glucose tolerance status			< 0.001			< 0.001
normoglycaemic	713 (81.8%)	219 (46.7%)		178 (80.9%)	61 (36.7%)	
prediabetes	123 (14.1%)	158 (33.7%)		30 (13.6%)	65 (39.2%)	
diabetes	36 (4.1%)	92 (19.6%)		12 (5.5%)	40 (24.1%)	
Antihypertensive medication	179 (20.5%)	190 (40.5%)	< 0.001	35 (15.9%)	63 (38.0%)	< 0.001
Antithrombotic medication	48 (5.5%)	54 (11.5%)	< 0.001	7 (3.2%)	14 (8.4%)	0.024
Lipid lowering medication	60 (6.9%)	49 (10.4%)	0.023	16 (7.3%)	25 (15.1%)	0.014
History of CVD	50 (5.7%)	43 (9.2%)	0.018	NA		

Values are expressed as the mean (SD) for normally distributed continuous variables or median (interquartile range) for non-normally distributed continuous variables, or n (%) for categorical variables.

Hepatic fat content was quantified on the level of portal vein by MRI proton density fat fraction (PDFF). FLD (PDFF >5.6%) was defined according to the EASL-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Results with *p* value <0.05 are shown in bold.

Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; GGT, Gamma-Glutamyl Transferase; CVD, cardiovascular disease, including myocardial infarction, stroke and angina pectoris; SD, standard deviation; NA, not applicable.

Supplemental table II. Differences in subclinical vascular disease parameters between participants with and without fatty liver disease (FLD) in SHIP and KORA.

	SHIP				KORA			
	No FLD (N=872)	FLD (N=469)	N missing	p value	No FLD (N=220)	FLD (N=166)	N missing	p value
Ascending aorta diameter (cm)	3.23 (0.45)	3.50 (0.42)	131	< 0.001	2.88 (0.40)	3.07 (0.40)	19	< 0.001
Descending aorta diameter (cm)	2.37 (0.33)	2.63 (0.31)	130	< 0.001	2.04 (0.30)	2.18 (0.30)	19	< 0.001
Infrarenal aorta diameter (cm)	1.80 (0.22)	1.93 (0.22)	105	< 0.001	1.46 (0.21)	1.57 (0.20)	19	< 0.001
Plaque presence	239 (27.4%)	228 (48.7%)	2	< 0.001	31 (20.3%)	23 (21.1%)	124	0.868
Type of plaque	NA	NA					124	0.910
AHA type I					122 (79.7%)	86 (78.9%)		
AHA type III					23 (15.0%)	15 (13.8%)		
AHA type V					5 (3.3%)	5 (4.6%)		
AHA type VI or VII					3 (2.0%)	3 (2.8%)		
Carotid intima-Media thickness (mm)	0.57 (0.13)	0.65 (0.14)	2	< 0.001	NA	NA		
Wall thickness, LCA (mm)	NA				0.71 (0.68, 0.76)	0.75 (0.70, 0.82)	135	0.003
Wall thickness, RCA (mm)	NA				0.72 (0.68, 0.80)	0.75 (0.71, 0.82)	129	0.003
Lumen area, LCA (mm²)	NA				16.37 (13.59, 20.54)	18.35 (15.36, 22.34)	131	0.093
Lumen area, RCA (mm²)	NA				14.98 (11.79, 20.28)	17.08 (14.34, 21.34)	124	0.038
Wall area, LCA (mm²)	NA				11.82 (10.15, 13.51)	12.84 (11.67, 14.39)	135	0.003
Wall area, RCA (mm²)	NA				11.14 (10.02, 13.69)	12.81 (11.57, 14.36)	129	0.003
NWI,LCA	NA				0.44 (0.04)	0.44 (0.05)	135	0.774
NWI,RCA	NA				0.45 (0.05)	0.45 (0.05)	129	0.719

Values are expressed as the mean (SD) for continuous variables, or n (%) for categorical variables. Results with p value < 0.05 are shown in bold.

Hepatic fat content was quantified on the level of portal vein by MRI proton density fat fraction (PDFF). FLD (PDFF >5.6%) was defined according to the EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Results with p value <0.05 are shown in bold.

Abbreviations: AHA, American Heart Association; LCA, left carotid artery; RCA, right carotid artery; NWI, normalized wall index, calculated as (wall area/(lumen area + wall area); NA, not applicable.

Supplemental table III. Associations of hepatic fat content and subclinical disease parameters according to glucose tolerance status (normoglycaemia vs altered glucose metabolism) in the KORA study.

	N	Model 1	<i>p</i> value	Model 2	<i>p</i> value	Model 3	<i>p</i> value
Altered glucose metabolism (prediabetes and diabetes)							
		OR, 95% CI		OR, 95% CI		OR, 95% CI	
Plaque Presence (n case = 24)	91	0.62 (0.37, 1.03)	0.067	0.52 (0.29, 0.94)	0.030	0.44 (0.21, 0.91)	0.027
Plaque type	91	0.60 (0.36, 0.99)	0.047	0.47 (0.26, 0.85)	0.014	0.39 (0.19, 0.79)	0.009
		β, 95% CI		β, 95% CI		β, 95% CI	
Wall thickness, LCA (mm)	87	-0.01 (-0.05, 0.02)	0.426	-0.02 (-0.06, 0.01)	0.219	-0.02 (-0.06, 0.03)	0.430
Wall thickness, RCA (mm)	90	-0.01 (-0.04, 0.02)	0.561	-0.02 (-0.05, 0.01)	0.275	-0.02 (-0.06, 0.01)	0.199
Lumen area, LCA (mm²)	89	0.02 (-0.07, 0.10)	0.666	0.0002 (-0.09, 0.09)	0.997	-0.01 (-0.12, 0.10)	0.886
Lumen area, RCA (mm²)	91	0.05 (-0.03, 0.14)	0.205	0.03 (-0.06, 0.12)	0.480	0.04 (-0.07, 0.14)	0.507
Wall area, LCA (mm²)	87	-0.004 (-0.07, 0.06)	0.910	-0.02 (-0.09, 0.04)	0.490	-0.01 (-0.09, 0.06)	0.730
Wall area, RCA (mm²)	90	0.02 (-0.04, 0.08)	0.550	-0.001 (-0.07, 0.06)	0.966	-0.01 (-0.08, 0.07)	0.848
NWI, LCA	87	-0.01 (-0.02, 0.01)	0.379	-0.01 (-0.02, 0.01)	0.342	-0.01 (-0.02, 0.01)	0.447
NWI, RCA	90	-0.01 (-0.02, -0.001)	0.042	-0.01 (-0.02, 0.0002)	0.059	-0.01 (-0.03, 0.0002)	0.058
Ascending aorta (cm)	135	0.06 (-0.004, 0.12)	0.068	0.01 (-0.06, 0.08)	0.812	0.01 (-0.07, 0.08)	0.886
Descending aorta (cm)	135	0.03 (-0.01, 0.08)	0.141	-0.01 (-0.05, 0.04)	0.822	-0.01 (-0.06, 0.04)	0.692
Infrarenal aorta (cm)	135	0.01 (-0.02, 0.04)	0.553	-0.01 (-0.04, 0.02)	0.570	-0.02 (-0.05, 0.02)	0.371
Normoglycaemia							
		OR, 95% CI		OR, 95% CI		OR, 95% CI	
Plaque Presence (n case = 30)	171	1.10 (0.69, 1.76)	0.697	1.13 (0.67, 1.90)	0.641	1.21 (0.69, 2.11)	0.507
Plaque type	171	1.11 (0.70, 1.76)	0.666	1.12 (0.67, 1.86)	0.679	1.13 (0.65, 1.95)	0.664
		β, 95% CI		β, 95% CI		β, 95% CI	
Wall thickness, LCA (mm)	164	0.01 (-0.02, 0.03)	0.615	-0.01 (-0.03, 0.01)	0.257	-0.01 (-0.03, 0.01)	0.280
Wall thickness, RCA (mm)	167	0.01 (-0.01, 0.03)	0.342	-0.01 (-0.03, 0.02)	0.572	-0.002 (-0.03, 0.02)	0.845
Lumen area, LCA (mm²)	166	0.004 (-0.05, 0.05)	0.871	-0.01 (-0.06, 0.05)	0.822	-0.001 (-0.06, 0.06)	0.960
Lumen area, RCA (mm²)	171	0.03 (-0.03, 0.09)	0.330	0.01 (-0.06, 0.07)	0.825	0.02 (-0.05, 0.08)	0.646
Wall area, LCA (mm²)	164	0.01 (-0.03, 0.04)	0.803	-0.02 (-0.06, 0.02)	0.302	-0.02 (-0.06, 0.03)	0.464
Wall area, RCA (mm²)	167	0.03 (-0.01, 0.06)	0.194	-0.004 (-0.05, 0.04)	0.861	0.01 (-0.03, 0.05)	0.715
NWI, LCA	164	0.003 (-0.004, 0.01)	0.435	-0.0002 (-0.01, 0.01)	0.961	-0.001 (-0.01, 0.01)	0.790
NWI, RCA	167	0.001 (-0.01, 0.01)	0.910	-0.001 (-0.01, 0.01)	0.841	-0.002 (-0.01, 0.01)	0.665
Ascending aorta (cm)	232	-0.002 (-0.05, 0.05)	0.921	-0.03 (-0.09, 0.02)	0.229	-0.05 (-0.11, 0.004)	0.073
Descending aorta (cm)	232	-0.01 (-0.04, 0.03)	0.794	-0.03 (-0.07, 0.01)	0.136	-0.03 (-0.07, 0.01)	0.118
Infrarenal aorta (cm)	232	0.01 (-0.02, 0.03)	0.547	-0.004 (-0.03, 0.02)	0.762	-0.003 (-0.03, 0.02)	0.829

Model 1: adjusted for age, sex

Model 2: Model 1 + BMI

Model 3: Model 2 + smoking, physical activity, alcohol intake, systolic blood pressure, HDL-C, LDL-C, triglycerides, antihypertensive medication, lipid lowering medication

Results with *p* value <0.05 are shown in bold. The coefficient estimates represent the change in subclinical disease parameters with a standard deviation increment of hepatic fat content.

Abbreviations: LCA, left carotid artery; RCA, right carotid artery; NWI, normalized wall index, calculated as wall area/(lumen area + wall area); BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; β, β-estimates from linear regression; CI, confidence interval.

Supplemental table IV. Associations of hepatic fat content with subclinical vascular disease parameters among participants without excessive alcohol intake in SHIP and KORA studies.

SHIP							
	N	Model 1 β, 95% CI	<i>p</i> value	Model 2 β, 95% CI	<i>p</i> value	Model 3 ^a β, 95% CI	<i>p</i> value
Aortic Diameters							
Ascending aorta (cm)	1,128	0.06 (0.04, 0.09)	< 0.001	0.02 (-0.01, 0.04)	0.219	0.01 (-0.02, 0.04)	0.533
Descending aorta (cm)	1,128	0.06 (0.04, 0.07)	< 0.001	0.01 (-0.002, 0.03)	0.092	0.01 (-0.01, 0.03)	0.294
Infrarenal aorta (cm)	1,128	0.02 (0.01, 0.03)	< 0.001	-0.01 (-0.02, 0.01)	0.416	0.0001 (-0.01, 0.01)	0.992
Carotid Plaque							
OR, 95% CI							
Plaque Presence	1,253	1.23 (1.06, 1.42)	0.008	1.12 (0.94, 1.34)	0.208	1.02 (0.83, 1.24)	0.861
β, 95% CI							
Carotid intima-media-thickness (mm)	1,253	0.01 (0.01, 0.02)	0.001	0.004 (-0.003, 0.01)	0.299	-0.001 (-0.01, 0.01)	0.740
KORA							
	N	Model 1 β, 95% CI	<i>p</i> value	Model 2 β, 95% CI	<i>p</i> value	Model 3 β, 95% CI	<i>p</i> value
Aortic Diameters							
Ascending aorta (cm)	271	0.03 (-0.02, 0.08)	0.197	-0.03 (-0.09, 0.02)	0.245	-0.04 (-0.11, 0.02)	0.201
Descending aorta (cm)	271	0.03 (-0.01, 0.06)	0.098	-0.02 (-0.06, 0.02)	0.407	-0.004 (-0.05, 0.04)	0.865
Infrarenal aorta (cm)	271	0.02 (0.002, 0.05)	0.032	0.01 (-0.02, 0.03)	0.697	0.002 (-0.03, 0.03)	0.918
Carotid Plaque							
OR, 95% CI							
Plaque Presence	201	1.02 (0.69, 1.50)	0.927	0.87 (0.56, 1.36)	0.546	0.68 (0.39, 1.19)	0.178
Plaque type	201	1.03 (0.71, 1.50)	0.870	0.83 (0.53, 1.29)	0.399	0.60 (0.34, 1.05)	0.072
β, 95% CI							
Wall thickness, LCA (mm)	193	0.02 (-0.01, 0.04)	0.167	-0.01 (-0.03, 0.02)	0.513	-0.01 (-0.04, 0.01)	0.306
Wall thickness, RCA (mm)	197	0.01 (-0.01, 0.03)	0.211	-0.01 (-0.03, 0.02)	0.592	-0.01 (-0.03, 0.02)	0.588
Lumen area, LCA (mm ²)	195	0.03 (-0.02, 0.08)	0.195	0.02 (-0.04, 0.08)	0.497	0.04 (-0.03, 0.11)	0.239
Lumen area, RCA (mm ²)	201	0.03 (-0.02, 0.09)	0.212	0.01 (-0.05, 0.07)	0.772	0.05 (-0.02, 0.13)	0.135
Wall area, LCA (mm ²)	193	0.03 (-0.01, 0.07)	0.158	-0.01 (-0.05, 0.04)	0.734	-0.01 (-0.06, 0.05)	0.861
Wall area, RCA (mm ²)	197	0.04 (-0.003, 0.08)	0.076	0.003 (-0.04, 0.05)	0.910	0.02 (-0.03, 0.07)	0.415
NWI, LCA	193	0.002 (-0.01, 0.01)	0.528	-0.002 (-0.01, 0.01)	0.605	-0.01 (-0.02, 0.003)	0.199
NWI, RCA	197	-0.002 (-0.01, 0.01)	0.677	-0.004 (-0.01, 0.004)	0.368	-0.01 (-0.02, -0.0004)	0.043

Model 1: adjusted for age, sex

Model 2: Model 1 + BMI

Model 3: Model 2 + Smoking, physical activity, alcohol intake, systolic blood pressure, HDL-C, LDL-C, triglycerides, glucose tolerance status, antihypertensive medication, lipid lowering medication

a. Model 3 in SHIP was additionally adjusted for history of cardiovascular diseases.

Results with *p* value <0.05 are shown in bold. The coefficient estimates represent the change in subclinical disease parameters with a standard deviation increment of log transformed hepatic fat content.

Abbreviations: LCA, left carotid artery; RCA, right carotid artery; NWI, normalized wall index, calculated as wall area/(lumen area + wall area); BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; β, β-estimates from linear regression; CI, confidence interval.

Supplemental table V. Sensitivity analyses with fatty liver disease (PDFF >5.6% or PDFF >5.1%) as exposure as well as replacing BMI with either VAT or waist circumference as covariate in SHIP and KORA studies.

SHIP								
	FLD ¹ (PDFF >5.6%)	<i>p</i> value	FLD ¹ (PDFF > 5.1%)	<i>p</i> value	VAT replacing BMI ² (PDFF as continuous exposure)	<i>p</i> value	Waist circumference replacing BMI ³ (PDFF as continuous exposure)	<i>p</i> value
	β, 95% CI		β, 95% CI		β, 95% CI		β, 95% CI	
Aortic Diameters								
Ascending aorta (cm)	-0.03 (-0.08, 0.02)	0.268	-0.02 (-0.07, 0.03)	0.469	0.01 (-0.02, 0.03)	0.669	-0.01 (-0.03, 0.02)	0.689
Descending aorta (cm)	0.01 (-0.02, 0.04)	0.569	0.02 (-0.01, 0.04)	0.309	0.004 (-0.01, 0.02)	0.664	0.00003 (-0.02, 0.02)	0.998
Infrarenal aorta (cm)	-0.002 (-0.03, 0.02)	0.852	-0.01 (-0.03, 0.02)	0.578	0.002 (-0.01, 0.02)	0.729	-0.004 (-0.02, 0.01)	0.494
Carotid Plaque								
Plaque Presence	1.08 (0.76, 1.55)	0.664	1.03 (0.72, 1.47)	0.888	1.07 (0.87, 1.31)	0.546	1.04 (0.85, 1.26)	0.720
Carotid intima-media-thickness (mm)	0.001 (-0.01, 0.01)	0.922	-0.003 (-0.02, 0.01)	0.658	-0.004 (-0.01, 0.004)	0.351	-0.01 (-0.01, 0.002)	0.187
KORA								
	FLD ¹ (PDFF >5.6%)	<i>p</i> value	FLD ¹ (PDFF > 5.1%)	<i>p</i> value	VAT replacing BMI ² (PDFF as continuous variable)	<i>p</i> value	Waist circumference replacing BMI ³ (PDFF as continuous variable)	<i>p</i> value
	β, 95% CI		β, 95% CI		β, 95% CI		β, 95% CI	
Aortic Diameters								
Ascending aorta (cm)	-0.03 (-0.13, 0.06)	0.497	-0.05 (-0.14, 0.05)	0.332	-0.03 (-0.09, 0.03)	0.260	-0.05 (-0.11, 0.002)	0.060
Descending aorta (cm)	-0.03 (-0.10, 0.03)	0.324	-0.02 (-0.08, 0.05)	0.651	-0.01 (-0.06, 0.03)	0.514	-0.03 (-0.07, 0.004)	0.079
Infrarenal aorta (cm)	-0.01 (-0.05, 0.04)	0.798	-0.0003 (-0.04, 0.04)	0.991	-0.01 (-0.03, 0.02)	0.576	-0.02 (-0.04, 0.01)	0.219
Carotid Plaque								
Plaque Presence	0.72 (0.31, 1.66)	0.444	0.74 (0.32, 1.72)	0.483	0.68 (0.39, 1.18)	0.173	0.79 (0.48, 1.31)	0.364
Plaque type	0.66 (0.29, 1.52)	0.329	0.69 (0.30, 1.59)	0.383	0.60 (0.34, 1.06)	0.077	0.72 (0.43, 1.21)	0.213
Wall thickness, LCA (mm)	0.004 (-0.04, 0.04)	0.836	0.002 (-0.04, 0.04)	0.936	-0.01 (-0.04, 0.01)	0.319	-0.02 (-0.04, 0.01)	0.205
Wall thickness, RCA (mm)	0.002 (-0.04, 0.04)	0.901	0.002 (-0.04, 0.04)	0.930	0.001 (-0.02, 0.03)	0.924	-0.01 (-0.03, 0.01)	0.339
Lumen area, LCA (mm ²)	0.02 (-0.08, 0.13)	0.679	0.05 (-0.06, 0.16)	0.356	0.03 (-0.04, 0.09)	0.391	-0.0004 (-0.06, 0.06)	0.991
Lumen area, RCA (mm ²)	0.06 (-0.05, 0.17)	0.316	0.05 (-0.06, 0.16)	0.399	0.07 (-0.001, 0.14)	0.054	0.03 (-0.03, 0.10)	0.308
Wall area, LCA (mm ²)	0.02 (-0.06, 0.09)	0.617	0.02 (-0.06, 0.09)	0.701	-0.002 (-0.05, 0.05)	0.944	-0.02 (-0.06, 0.03)	0.414
Wall area, RCA (mm ²)	0.03 (-0.05, 0.10)	0.462	0.02 (-0.05, 0.10)	0.566	0.03 (-0.01, 0.08)	0.164	0.004 (-0.04, 0.05)	0.850
NWI, LCA	-0.002 (-0.02, 0.01)	0.775	-0.003 (-0.02, 0.01)	0.644	-0.01 (-0.02, 0.002)	0.113	-0.003 (-0.01, 0.01)	0.548
NWI, RCA	-0.01 (-0.02, 0.01)	0.334	-0.01 (-0.02, 0.01)	0.412	-0.01 (-0.02, -0.0003)	0.045	-0.01 (-0.02, 0.001)	0.099

1. Model adjustment: age, sex, BMI, Smoking status, physical activity, alcohol intake, systolic blood pressure, HDL-C, LDL-C, triglycerides, glucose tolerance status, use of antihypertensive medication, use of lipid lowering medication, CVD (only in SHIP)

In this model, FLD was defined by either PDFF > 5.6% according to the EASL-EASD-EASO Clinical Practice Guideline for the management of non-alcoholic fatty liver disease or PDFF > 5.1% according to Kühn et al.²

2. Model adjustment: age, sex, VAT, Smoking status, physical activity, alcohol intake, systolic blood pressure, HDL-C, LDL-C, triglycerides, glucose tolerance status, use of antihypertensive medication, use of lipid lowering medication, CVD (only in SHIP)

3. Model adjustment: age, sex, waist circumference, Smoking status, physical activity, alcohol intake, systolic blood pressure, HDL-C, LDL-C, triglycerides, glucose tolerance status, use of antihypertensive medication, use of lipid lowering medication, CVD (only in SHIP)

Results with *p* value <0.05 are shown in bold.

Abbreviations: FLD, fatty liver disease; PDFF, proton density fat fraction; LCA, left carotid artery; RCA, right carotid artery; NWI, normalized wall index, calculated as wall area/(lumen area + wall area); BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VAT, visceral adipose tissue; OR, odds ratio; β, β-estimates from linear regression; CI, confidence interval.

Supplemental table VI. Associations of hepatic fat content with subclinical vascular disease parameters among participants without cardiovascular disease history in SHIP study.

	N	Model 1 β, 95% CI	<i>p</i> value	Model 2 β, 95% CI	<i>p</i> value	Model 3 β, 95% CI	<i>p</i> value
Ascending aorta (cm)	1120	0.06 (0.03, 0.08)	< 0.001	0.004 (-0.02, 0.03)	0.754	-0.004 (-0.03, 0.02)	0.760
Descending aorta (cm)	1120	0.05 (0.04, 0.06)	< 0.001	0.01 (-0.01, 0.02)	0.400	0.002 (-0.01, 0.02)	0.853
Infrarenal aorta (cm)	1120	0.02 (0.01, 0.03)	0.001	-0.01 (-0.02, 0.003)	0.158	-0.004 (-0.02, 0.01)	0.523
Plaque Presence	1246	OR, 95% CI 1.21 (1.04, 1.41)	0.014	OR, 95% CI 1.13 (0.95, 1.35)	0.177	OR, 95% CI 1.06 (0.87, 1.29)	0.558
Intima-media-thickness (mm)	1246	β, 95% CI 0.01 (0.002, 0.01)	0.007	β, 95% CI 0.001 (-0.01, 0.01)	0.873	β, 95% CI -0.004 (-0.01, 0.003)	0.277

Model 1: adjusted for age, sex

Model 2: Model 1 + BMI

Model 3: Model 2 + smoking, physical activity, alcohol intake, systolic blood pressure, HDL-C, LDL-C, triglycerides, glucose tolerance status, antihypertensive medication, lipid lowering medication

Results with *p* value <0.05 are shown in bold. The coefficient estimates represent the change in subclinical disease parameters with a standard deviation increment of hepatic fat content.

Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; β, β-estimates from linear regression; CI, confidence interval.